Oppenheimer, Cowen, H.C. Wainwright Maintain Buy/Outperform on OLMA March 2026
OLMA analyst rating updates on March 9, 2026 show three firms kept positive calls on Olema Pharmaceuticals, Inc. (OLMA). The key takeaway is consensus support: Oppenheimer kept an Outperform, while Cowen & Co. and H.C. Wainwright each maintained Buy on the name. These actions followed clinical and program news and coincided with intraday share moves of -8.37%, -8.33%, and -12.06% across the three reports. Investors should read these ratings as continued analyst conviction, not as guarantees of near-term gains.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
